- Home
- LKFT vs COAG Comparison
LKFT vs COAG Comparison
Compare LKFT & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LKFT | COAG |
|---|---|---|
| Founded | 1999 | 2020 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2007 | 2026 |
Fundamental Metrics
Financial Performance| Metric | LKFT | COAG |
|---|---|---|
| Price | $31.70 | $34.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $30.21 | ★ $62.67 |
| AVG Volume (30 Days) | 256.8K | ★ 347.8K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.68 | $27.38 |
| 52 Week High | $32.41 | $55.42 |
Technical Indicators
Market Signals| Indicator | LKFT | COAG |
|---|---|---|
| Relative Strength Index (RSI) | 66.24 | 50.57 |
| Support Level | $28.50 | $28.46 |
| Resistance Level | $32.41 | $38.87 |
| Average True Range (ATR) | 0.76 | 2.56 |
| MACD | 0.17 | 1.02 |
| Stochastic Oscillator | 96.66 | 76.54 |
Price Performance
Historical ComparisonAbout LKFT Lakefront Biotherapeutics American Depositary Shares
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
About COAG Hemab Therapeutics Holdings Inc. Common Stock
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.